More Life Sciences Headlines
Biogen CEO to resign, Alzheimer’s drug sales division is dismantled
Michel Vounatsos will stay on until a replacement is found, and the Cambridge biotech will continue research on Alzheimer's despite the failure of Aduhelm.
Biogen CEO to step down after company’s struggles with Aduhelm
The announcement represents a stark acknowledgement that the Cambridge company has failed to find a place for a drug that was expected to drive its business for years to come.
Vertex stock falls after FDA halts diabetes study in surprise move
Vertex Pharmaceuticals shares tumbled after US regulators placed its study of a key new treatment for type 1 diabetes on clinical hold.
AstraZeneca to open major research center in Kendall Square
The pharma giant will move out of its Waltham labs and Seaport location into a new 16-story building.
FDA will consider applications for young children’s vaccines in June
Moderna said it would complete its FDA application next week; Pfizer will do so in the next few weeks.
Apertura Gene Therapy launches with $67m to design new viruses for gene delivery
The startup is based on the work of scientists at the Broad Institute and Harvard Medical School
Symeres acquires Woburn chemistry firm Organix for its lipid expertise
The Dutch buyer is one of the largest European contract research firms focused on the discovery, testing, and manufacturing of drugs.
Boston’s Ginkgo and German giant Bayer AG strike partnership
The announcement signals the winding down of Joyn Bio, a joint venture the two companies started in 2017 to explore how to make more sustainable agricultural products through biology.